In this week’s Xtalks Life Science podcast episode, Sarah spoke with Doug Biehn, Chief Commercial Officer at Cala Health, a bioelectronic medicine company that develops wearable neuromodulation therapies.

The company’s lead product, Cala Trio, was approved by the US Food and Drug Administration (FDA) in 2018 for transient relief of hand tremors in adults with essential tremor (ET).

Tune into the episode to learn more about Cala Health’s individualized prescription neuromodulation therapy. Doug discussed the day-to-day struggles of patients with ET and the challenges they face when seeking medication for their condition. Doug also shared the benefits of Cala Trio for the relief of hand tremors and how company is committed to ensuring all patients have access to this life-changing neuromodulation therapy.

Follow Us on Social Media

Twitter: @Xtalks